Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and extended-release metformin hydrochloride 2000 mg.
This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse effects associated with metformin use, the metformin hydrochloride dose should be increased gradually.
Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily.
Patients taking this drug as a 2.5/750 mg or 2.5/1000 mg extended-release tablet should take 2 tablets together once daily.
1. Patients not currently treated with metformin:
The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000 mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving treatment with metformin
- For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's existing dose of metformin hydrochloride, according to the current treatment regimen.
- For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's existing dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with Caution in the Following Patients).
- When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted appropriately if necessary.
-When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the existing doses of linagliptin and extended-release metformin hydrochloride.
Special populations
Renal impairment
As dose adjustment according to renal function is necessary, evaluation of renal function is recommended before treatment with this drug and periodically thereafter.
No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73m2].
In patients with moderate renal impairment (CKD stage 3A), with creatine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis.
The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this drug must be discontinued immediately.
Improvement of blood glucose control in type 2 diabetes mellitus
View approved original textHide original text
This medication is used to assist blood sugar control in patients with type 2 diabetes by combining linagliptin and metformin. It is primarily prescribed for patients who are also implementing meal control and exercise therapy, and improvements in blood sugar levels can be expected. Therefore, it is a very useful therapeutic agent for diabetes management.
How to take
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and extended-release metformin hydrochloride 2000 mg.
This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse effects associated with metformin use, the metformin hydrochloride dose should be increased gradually.
Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily.
Patients taking this drug as a 2.5/750 mg or 2.5/1000 mg extended-release tablet should take 2 tablets together once daily.
1. Patients not currently treated with metformin:
The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000 mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving treatment with metformin
- For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's existing dose of metformin hydrochloride, according to the current treatment regimen.
- For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's existing dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with Caution in the Following Patients).
- When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted appropriately if necessary.
-When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the existing doses of linagliptin and extended-release metformin hydrochloride.
Special populations
Renal impairment
As dose adjustment according to renal function is necessary, evaluation of renal function is recommended before treatment with this drug and periodically thereafter.
No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73m2].
In patients with moderate renal impairment (CKD stage 3A), with creatine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis.
The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this drug must be discontinued immediately.
Precautions
This medication can rarely cause serious lactic acidosis or hypoglycemia, so caution is required.
It should not be used in patients with allergies to the active ingredients or components, in type 1 diabetes patients, or in certain patient groups with severely impaired renal function.
This medication should not be administered in situations like dehydration, severe infections, or acute myocardial infarction, where the physical condition may rapidly deteriorate, nor in patients with impaired liver function.
When used in conjunction with sulfonylureas or insulin, there is a risk of hypoglycemia, so it is important to carefully monitor blood sugar levels and adjust dosages of other medications as necessary.
Lactic acidosis is very rare but can be fatal, so if symptoms such as abdominal pain, muscle weakness, or difficulty breathing occur, immediate medical attention should be sought.
Since renal function plays an important role in the excretion of this medication, regular kidney function tests should be conducted before and during treatment, and discontinuation may be necessary if renal function declines.
Patients with weak heart function should periodically check their heart and kidney function while using this medication.
This medication should be temporarily discontinued before examinations that use radiological iodine contrast agents, and resumed only after confirming stable renal function post-examination.
Patients scheduled for surgery should stop taking this medication 48 hours prior to surgery and resume only after confirming that renal function has recovered post-surgery.
If acute pancreatitis or blistering skin disease is suspected, this medication should be discontinued immediately and medical personnel consulted.
This medication may lower vitamin B12 levels, so long-term users should have blood tests to monitor vitamin B12 status and supplement as necessary.
This medication should be swallowed whole, and while the tablet coating may be excreted, this is a normal occurrence.
There may be interactions with other medications, so all medications being taken should be disclosed to medical personnel, especially caution is needed with drugs that can affect renal function.
It is advisable to avoid using this medication during pregnancy or breastfeeding, and to consult with medical personnel if pregnancy is planned.
Safety in children has not been established, and elderly patients should be carefully monitored due to the potential for decreased renal function.
In case of overdose, gastrointestinal symptoms or lactic acidosis may occur, requiring immediate medical treatment.
This medication should be kept out of reach of children and stored away from moisture and direct sunlight.
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius to safely preserve its efficacy.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.